IDO1 and neoplasm: Despite the unpromising results of previous clinical trials with IDO inhibitors, numerous preclinical studies suggest that the inhibition of the KP enzymes may still prove to be an effective solution in cases remaining a challenge for modern oncology, especially the tumor immune escape and resistance to chemotherapy and immunotherapy.